Novo Nordisk Slashes Wegovy Sales Forecasts Amid Compounding Controversy
Novo Nordisk’s shares have plummeted over 20% after the company announced a significant cut to its forecast for Wegovy, its flagship obesity medication. The move is attributed to cheaper alternatives made by compounding pharmacies, which have increased in popularity due to the shortage of Wegovy. In May, Novo Nordisk had predicted that Wegovy sales would … Read more